Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Simian immunodeficiency virus (SIV) envelope glycoprotein gp120 is the surface subunit of the viral envelope (Env) complex, essential for the infection of host cells [UniProt, https://www.uniprot.org/uniprotkb/P05884/entry]. It is produced by the proteolytic cleavage of the gp160 precursor into gp120 and the transmembrane subunit gp41, which together form trimeric spikes on the virion surface [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120343/]. Gp120's primary function is to mediate viral attachment by binding to the host CD4 receptor and a chemokine co-receptor, typically CCR5, which triggers conformational changes in gp41 to initiate membrane fusion [Wikipedia, https://en.wikipedia.org/wiki/Envelope_glycoprotein_GP120]. As the most exposed viral protein, it is the primary target for neutralizing antibodies and a central focus for vaccine and entry inhibitor development [PubMed, https://pubmed.ncbi.nlm.nih.gov/26324120/]. However, gp120 employs sophisticated evasion strategies, including extensive N-linked glycosylation (the glycan shield) and high sequence variability in its five variable loops (V1-V5), which present significant challenges for therapeutic targeting [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403475/]. In research models, SIV gp120 serves as a vital surrogate for understanding HIV-1 pathogenesis and testing novel interventions like broadly neutralizing antibodies and attachment inhibitors [Science, https://www.science.org/doi/10.1126/science.aag1619].
Attachment inhibition, Entry inhibition, Neutralization, Receptor mimicry
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Simian immunodeficiency virus envelope glycoprotein gp120 (SIV gp120).